on Mainz BioMed N.V.
Mainz Biomed and CARE Partner for Enhanced Cancer Screening
Mainz Biomed N.V., a leader in cancer diagnostics, has announced a strategic partnership with CARE diagnostica Laborreagenzien GmbH. This collaboration aims to enhance colorectal cancer screening services for health insurance companies in Germany.
CARE currently collaborates with 19 health insurance companies, offering online-based screening using fecal immunochemical tests (FIT). The new partnership will broaden services to include Mainz Biomed's ColoAlert®, which utilizes molecular genetic analysis for early cancer detection.
This agreement, effective immediately, aligns with the increasing demand for personalized and early intervention diagnostic solutions. It further consolidates Mainz Biomed's presence in the German market, expanding distribution of ColoAlert® and meeting rising consumer needs.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mainz BioMed N.V. news